⌘K

Home/Filings/4/0001209191-22-056248

4//SEC Filing

DiFabio Andrea 4

Accession 0001209191-22-056248

CIK 0001582313other

View on SEC.gov Company Profile

Filed

Nov 8, 7:00 PM ET

Accepted

Nov 9, 5:04 PM ET

Size

5.4 KB

Accession

0001209191-22-056248

Insider Transaction Report

Form 4

Period: 2022-11-07

Xenon Pharmaceuticals Inc.XENE

Chief Legal Officer

Transactions

Award
Stock Option (Right to Buy)
2022-11-07+135,000→ 135,000 total
Exercise: $34.77Exp: 2032-11-06→ Common Shares (135,000 underlying)

Footnotes (1)

[F1]Vesting 25% on the one year anniversary of the grant date, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Xenon Pharmaceuticals Inc.

CIK 0001582313

Entity typeother

Related Parties

1

filerCIK 0001692506

Filing Metadata

Form type: 4
Filed: Nov 8, 7:00 PM ET
Accepted: Nov 9, 5:04 PM ET
Size: 5.4 KB

View on SEC.gov